DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Canada
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
ACB logo

Aurora Cannabis Inc. Stock Price

TSX:ACB Community·CA$334.7m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 71 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ACB Share Price Performance

CA$5.17
-1.59 (-23.52%)
​
CA$5.38
Fair Value
CA$5.17
-1.59 (-23.52%)
3.9% undervalued intrinsic discount
CA$5.38
Fair Value
Price CA$5.17
AnalystConsensusTarget CA$5.38
AnalystLowTarget CA$4.00
AnalystHighTarget CA$8.00
Thu, 20 Aug 26
Fair ValueCA$5.38
Share Pricen/a

ACB Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CA$5.38 3.9% undervalued intrinsic discount

European And Australian Medical Cannabis Markets Will Unlock Enduring Potential

0users have liked this narrative
0users have commented on this narrative
36users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value CA$4 29.3% overvalued intrinsic discount

European Cannabis Regulations And Intense Competition Will Hamper Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value CA$8 35.4% undervalued intrinsic discount

Global Cannabis Legalization And Medical Integration Will Expand Wellness Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ACB logo
Aurora Cannabis
3.9% undervalued intrinsic discount

European And Australian Medical Cannabis Markets Will Unlock Enduring Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 20 Aug
Read Narrative
ACB logo
Aurora Cannabis
29.3% overvalued intrinsic discount

European Cannabis Regulations And Intense Competition Will Hamper Expansion

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 27 Jul
Read Narrative
ACB logo
Aurora Cannabis
35.4% undervalued intrinsic discount

Global Cannabis Legalization And Medical Integration Will Expand Wellness Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 7 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
ACB logo

ACB: Curaleaf Bid And Medical Refocus Will Shape Fairly Valued Outlook

Fair Value: CA$5.38 3.9% undervalued intrinsic discount
36 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
ACB logo

ACB: Medical Refocus And Impairment Charges Will Shape Balanced Outlook

Fair Value: CA$4 29.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
ACB logo

ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential

Fair Value: CA$8 35.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet and good value.

0 Risks
2 Rewards
View Full Analysis

Aurora Cannabis Inc. Key Details

CA$314.1m

Revenue

CA$175.3m

Cost of Revenue

CA$138.7m

Gross Profit

CA$191.2m

Other Expenses

-CA$52.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.81
44.18%
-16.71%
0%
View Full Analysis

About ACB

Founded
2013
Employees
1028
CEO
Miguel Martin
WebsiteView website
www.auroramj.com

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty’s, Whistler, and WMMC. The company also engages in pharmacy activities. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.

Recent ACB News & Updates

User avatar
Narrative Update • Aug 20

ACB: Curaleaf Bid And Medical Refocus Will Shape Fairly Valued Outlook

Analysts have trimmed their price expectations for Aurora Cannabis, with the fair value estimate moving from CA$6.14 to CA$5.38 as they factor in a higher discount rate, revised revenue growth assumptions, a much higher future P/E, and weaker projected profit margins. What's in the News for Aurora Cannabis Curaleaf Holdings has proposed to acquire Aurora Cannabis for approximately US$270 million, offering Aurora shareholders 0.3463 Curaleaf shares plus US$0.75 in cash per Aurora share, with implied premiums referenced to Aurora's 30 day volume weighted average price.

Recent updates

No updates

Aurora Cannabis Inc. Competitors

GUD logo

Knight Therapeutics

Symbol: TSX:GUD
Market cap: CA$955.8m
DRUG logo

Bright Minds Biosciences

Symbol: CNSX:DRUG
Market cap: CA$875.0m
VREO logo

Vireo Growth

Symbol: CNSX:VREO
Market cap: CA$814.8m
EPRX logo

Eupraxia Pharmaceuticals

Symbol: TSX:EPRX
Market cap: CA$730.2m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide